Tudor Investment Corp’s Autolus Therapeutics AUTL Stock Holding History

Tudor Investment Corp’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63.8K	Sell	46,213 -235,900	-84%	-$358K	﹤0.01%	3485
2025 Q4	$561K	Buy	282,113 +75,460	+37%	+$116K	﹤0.01%	2663
2025 Q3	$337K	Buy	206,653 +100,000	+94%	+$195K	﹤0.01%	2909
2025 Q2	$243K	Buy	+106,653	New	+$176K	﹤0.01%	2999
2021 Q3	–	Sell	-13,991	Closed	-$93K	–	2438
2021 Q2	$93K	Buy	+13,991	New	+$86.8K	﹤0.01%	1535
2020 Q3	–	Sell	-26,513	Closed	-$425K	–	1281
2020 Q2	$425K	Sell	26,513 -18,046	-40%	-$200K	0.02%	775
2020 Q1	$267K	Buy	+44,559	New	+$412K	0.02%	719

Other funds holding AUTL

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tudor Investment Corp's AUTL Position: Q1 2026 in Review

Tudor Investment Corp reduced its Autolus Therapeutics (AUTL) stake by 84% in Q1 2026, selling an estimated $358K and leaving 46,213 shares worth $63.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Tudor Investment Corp first reported a position in AUTL in Q1 2020 and has held it in 7 quarters since. The position peaked at $561K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

Tudor Investment Corp held 46,213 shares of Autolus Therapeutics worth $63.8K as of Q1 2026.
Tudor Investment Corp sold 235,900 Autolus Therapeutics shares in Q1 2026, an estimated $358K.
Autolus Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #3485 holding.
Tudor Investment Corp first reported a position in Autolus Therapeutics in Q1 2020 and has held it in 7 quarters since.
Tudor Investment Corp's Autolus Therapeutics position peaked at $561K in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.